The largest database of trusted experimental protocols

Anti human cd8 clone c8 144b

Manufactured by Agilent Technologies
Sourced in United States, Denmark

The Anti-Human CD8 (clone C8/144B) is a laboratory reagent used for the identification and enumeration of human CD8-positive T cells. It is a monoclonal antibody that specifically binds to the CD8 cell surface antigen expressed on a subset of T lymphocytes.

Automatically generated - may contain errors

8 protocols using anti human cd8 clone c8 144b

1

Multiplexed IF Profiling of Tumor Immune Landscape

Check if the same lab product or an alternative is used in the 5 most similar protocols
Multiplexed IF was performed on a total of 45 FFPE samples (29 pre-BCG tumor and 16 post-BCG specimens) with the Opal system and images were acquired using the Vectra 3.0 Automated Quantitative Pathology Imaging System (Perkin Elmer) with 4′,6-diamidino-2-phenylindole (DAPI) as the nuclear marker as previously described (26 (link)). The antibodies used are anti-Human CD4 (clone EPR6855; Abcam), anti-Human CD8 (clone C8/144B; DAKO), anti-Human FOXP3 (clone 236A/E7; Abcam), and anti-Human PD-1 (clone NAT105; Abcam). From these 45 FFPE samples, another single-plexed staining of PD-L1, anti-human PD-L1 antibody (clone 22C3; DAKO), was separately performed on consecutive slide of 12 samples (six pairs of matched pre- and post-BCG tumor from non-responders). Full tissue sections were used for all samples. For specimens smaller than 1cmx0.5cm, whole tissue was imaged and quantified; whereas for specimens larger than 1cmx0.5cm, at least 10 areas of 2 mm x 3 mm with high infiltration of immune cells were imaged and quantified. Quantification was done by ImageJ and the mean was calculated as the cell density (number/mm2) for each patient sample, while area with PD-L1 positive staining was quantified and the mean was reported as PD-L1+area/mm2. The median value of density for each immune subsets was used as the cutoff point to dichotomize the patients into two groups (low versus high).
+ Open protocol
+ Expand
2

Immunohistochemical Quantification of Placental Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
In formalin-fixed, paraffin embedded tissues, the EnVision system (Dako) with anti-Human CD4 (Clone 4B12, Dako), anti-Human CD8 (Clone C8/144B, Dako), anti-Human CD14 (Clone TÜK4, Dako), anti-Human CD56 (Clone 123C3), and anti-Human CD68 (Clone PG-M1, Dako), was used. Briefly, the paraffin sections were deparaffinized and rehydrated in xylene and graded alcohols. After blocking with peroxidase in ChemMate peroxidase-blocking solution (Dako), the slides were incubated with the primary antibodies. After application of the peroxidase-labeled polymer, the slides were incubated with the diaminobenzidine substrate chromogen solution, counterstained with hematoxylin, washed again, dehydrated, and mounted. The immunohistochemical slides were observed using a Zeiss Axio Imager M2 light microscope equipped with a Zeiss Axio Cam HRc Camera to capture images of the placenta. Ten photos were collected per slide, with 40X objective lens. Subsequently, each photograph was analyzed and the number of cells counted for each photo. The number of positive cells was calculated and analyzed using the Image J software (Image J 1.46r Wayne Rasband National Institutes of Health, USA, https://imagej.nih.gov/ij/index.html).
+ Open protocol
+ Expand
3

Immunohistochemical Analysis of FFPE Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
p16 IHC on formalin-fixed, paraffin-embedded (FFPE) tumor tissue was performed as part of the routine diagnostics process (Supplementary Table 1). Additional IHC was performed on FFPE tissue using standard protocols for the automated platforms Dako PT Link for Heat Induced Epitope Retrieval and Dako Autostainer 48S Link (Agilent, Santa Clara, CA, USA) with staining of tumor-infiltrating lymphocytes using anti-CD8 antibodies (Anti-Human CD8, Clone C8, 144B, Dako, concentration: 1:100, Agilent, Santa Clara, CA, USA). An unsuccessful immunohistochemical approach for HPV16 E2 and E7 was performed with following antibodies [Anti-HPV16 E2, NBP2-53115, NovusBio (no literature), Centennial, CO, USA; Anti-HPV16 E7, ab20191, Abcam, Cambridge, UK (32 ); Anti-HPV16 E7 (716–325), sc-51951, Santa Cruz Biotechnology, Dallas, TX, USA (33 (link))]. Different concentrations and antigen retrieval techniques revealed still unspecific staining.
Frequency and density of CD8 positive T cells were determined as previously described (34 (link), 35 (link)). One case was excluded in the further IHC analysis due to non-specific IHC staining.
+ Open protocol
+ Expand
4

Multiplexed IHC Profiling of Tumor Immune Landscape

Check if the same lab product or an alternative is used in the 5 most similar protocols
Multiplexed fluorescent immunohistochemistry was performed using the tyramide signal amplification method with an Opal IHC kit (Akoya Biosciences, Marlborough, MA, USA) according to the manufacturer's instructions. Tissue sections, of thickness 4 μm, were cut from FFPE tumor specimens and then baked at 60 °C onto adhesive glass slides for 30 min before deparaffinization. The primary antibodies used were anti‐human CD8 (clone C8/144b; DAKO), anti‐human T‐bet (Santa Cruz Biotechnology, Dallas, TX, USA), and cytokeratin (clone AE1/AE3; DAKO). A high‐pH target‐retrieval solution (DAKO) was used for antigen retrieval, and immunoactive buffer (Matsunami Glass, Osaka, Japan) was used for antibody stripping. Opal 520, 540, and 650 were used for labeling CD8, T‐bet, and cytokeratin, respectively. A horseradish peroxidase‐labeled secondary detection system (EnVision Plus, DAKO) was used as a catalyst for fluorophore‐conjugated tyramide. Heating at 95 °C for 20 min was performed for primary antigen unmasking and antibody stripping after each fluorescent labeling.
+ Open protocol
+ Expand
5

Immunophenotyping of HNSCC Tumor Microenvironment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Paraffin sections of primary HNSCC tumors were stained with anti-human CD3 (clone SP7; Thermo Scientific, USA), anti-human CD8 (clone C8/144B; Dako), anti-human CD20 (clone L26; Dako), anti-human CD68 (clone PG-M1; Dako), anti-human CD56 (clone 123C3; Invitrogen), and anti-human CD163 (clone MRQ-26; Cell Marque) antibodies using the BOND-MAX automated IHC-stainer (Leica Biosystems) according to the manufacturer’s instructions in the Institute of Pathology (University of Cologne, Germany). Numbers of infiltrating cells in the invasive margin and tumor core of HNSCC sections were analyzed separately. Cell counts per high power field (HPF) at 400× magnification were assessed by an experienced pathologist in five HPF of invasive margin and tumor core of every slide, respectively, and the mean positive cell count per HPF was calculated.
+ Open protocol
+ Expand
6

Quantifying Immune Cell Populations in FFPE Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols
FFPE specimens were sectioned at five-micrometers and stained on the DISCOVERY XT platform (Ventana Medical Systems, Inc., Tucson, U.S.A). TAM and microglia were identified using antibodies against IBA1. Antibodies targeting CD3 and CD8 stained the entire T cell population and cytotoxic T cells, respectively. Regulatory T cells were stained by antibodies against forkhead box P3 (FOXP3). Due to the lack of a validated antibody, the CD4+ T cell number was estimated to be the difference between the CD3+ and CD8+ T cell numbers according to published protocol.35 In six cases, the number of CD8+ T cells exceeded or was identical to the number of CD3+ T cells, so that the CD4+ T cell population was considered to be equal to the FOXP3+ T cell number, since the latter constitutes a subpopulation of CD4+ T cells. The following primary antibodies were used: Anti-IBA1 (1:500, rabbit polyclonal, #019–19741, Wako Pure Chemical Ind., Ltd., Osaka, Japan); anti-human FOXP3, clone 259D (1:100, mouse monoclonal, #320202, BioLegend, San Diego, U.S.A); anti-human CD8, clone C8/144B (1:100, mouse monoclonal, code M7103, Dako, Glostrup, Denmark); anti-human CD3 (1:100, rabbit polyclonal, code A0452, Dako, Glostrup, Denmark).
+ Open protocol
+ Expand
7

Comprehensive Immunohistochemical Profiling of PDX Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
IHC assays were performed following established protocols [31 (link)]. After antigen retrieval (Tris-Cl, pH 9.0), paraffin-embedded sections of PDX tumors were incubated for 1 hour at room temperature with the following antibodies: antihuman CD45 (leukocyte common antigen, clones 2B11 + PD7/26); antihuman CD68, clone KP1; antihuman CD8 (clone C8/144B); antihuman CD4, clone 4B12; antihuman Ki-67, clone MIB-1 (Dako, Glostrup, Denmark); antihuman CD3, clone UCHT1 (STEMCELL Technologies); antihuman CD20, clone EP459Y; antihuman CD56, clone EPR2566 (Abcam, Cambridge, MA, USA); antihuman cytokeratin 19 (CK19), clone A53-B/A2.26, also known as Ks19.1 (Thermo Scientific, Waltham, MA, USA).
+ Open protocol
+ Expand
8

Immunohistochemical Analysis of Tumor Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following primary antibodies were used: anti-human CD8 (clone C8/144B, Dako, Glostrup, Denmark), anti-human CD68 (clone KP-1, Dako), and anti-human CD163 (clone 10D6,Leica Biosystems Novocastra, Newcastle, UK). Paraffin-embedded tumor specimens were cut into sequential 5 µm thick sections and deparaffinized and stained using a fully automated Ventana BenchMark ULTRA Stainer (Ventana, Tucson Arizona, USA) according to manufacturers' instructions at the pathology department. Binding of peroxidase-coupled antibodies was detected using 3,3′ - diaminobenzidine (DAB) as a substrate and the slides were counterstained with haematoxylin. The specificity of antibodies was checked using isotype-matched controls.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!